Myocardial ischemia risk in breast cancer patients may evolve over a longer time frame, and a longer follow‐up duration would allow for a more comprehensive evaluation of the relationship between serum ApoB and HER2 levels and myocardial ischemia risk [33]. This evidence concerns the gene ERBB2 and breast carcinoma.